Anti-metabolites
Chemotherapy + Bevacizumab for Abdominal Cancer
Recruiting1 awardPhase 1
Saint Louis, Missouri
This trial is testing a new cancer treatment combining two drugs, one given directly into the abdomen and one taken by mouth. It is for people with a certain kind of cancer that has spread into the abdomen, and who have had surgery to remove as much of the cancer as possible.
Popular Filters
Trials for Ovarian Cancer Patients
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
Recruiting1 awardPhase 1
Iowa City, Iowa
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Alkylating agents
Oregovomab + Chemo for Advanced Ovarian Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
Recruiting3 awardsPhase 3
Birmingham, Alabama
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
Checkpoint Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
Trials for Ovarian Tumors Patients
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
Recruiting1 awardPhase 1
Iowa City, Iowa
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Alkylating agents
Oregovomab + Chemo for Advanced Ovarian Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
Recruiting3 awardsPhase 3
Birmingham, Alabama
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
Checkpoint Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
Trials for BRCA1 Positive Patients
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
Recruiting1 awardPhase 1
Iowa City, Iowa
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
Recruiting3 awardsPhase 3
Birmingham, Alabama
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
Checkpoint Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
PD-1 Inhibitor
Niraparib + Dostarlimab for Cancer
Recruiting1 awardPhase 1
Seattle, Washington
This trial is testing the combination of two drugs to treat patients with BRCA-mutated cancer. Niraparib is an inhibitor of PARP, an enzyme that helps repair DNA. TSR-042 is an immunotherapy that may help the body's immune system attack the cancer.
Tyrosine Kinase Inhibitor
Olaparib vs. Cediranib + Olaparib for Recurrent Ovarian Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is comparing two different treatments for ovarian, fallopian tube, or primary peritoneal cancer that has come back. One treatment is a standard chemotherapy treatment, and the other is a new treatment that uses two drugs, olaparib and cediranib maleate. The trial will see if the new treatment is more effective than the standard chemotherapy treatment.
Trials for BRCA2 Positive Patients
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
Recruiting1 awardPhase 1
Iowa City, Iowa
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
Checkpoint Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
PD-1 Inhibitor
Niraparib + Dostarlimab for Cancer
Recruiting1 awardPhase 1
Seattle, Washington
This trial is testing the combination of two drugs to treat patients with BRCA-mutated cancer. Niraparib is an inhibitor of PARP, an enzyme that helps repair DNA. TSR-042 is an immunotherapy that may help the body's immune system attack the cancer.
Tyrosine Kinase Inhibitor
Olaparib vs. Cediranib + Olaparib for Recurrent Ovarian Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is comparing two different treatments for ovarian, fallopian tube, or primary peritoneal cancer that has come back. One treatment is a standard chemotherapy treatment, and the other is a new treatment that uses two drugs, olaparib and cediranib maleate. The trial will see if the new treatment is more effective than the standard chemotherapy treatment.
Monoclonal Antibodies
Tremelimumab + Olaparib for Recurrent Ovarian Cancer
Recruiting1 awardPhase 2
Orange, California
This trial is testing olaparib, a PARP inhibitor, with and without tremelimumab, an immunotherapy drug, to see if they are effective in treating patients with ovarian, fallopian tube, or peritoneal cancer that has returned.
Phase 3 Trials
Corticosteroid
Relacorilant + Nab-Paclitaxel for Ovarian Cancer
Recruiting2 awardsPhase 3
Rapid City, South Dakota
This trial tests a new combination of two drugs for ovarian cancer patients who have no other treatment options left. The combination includes a drug that may make chemotherapy more effective and a chemotherapy drug that has been used in various cancer treatments. The goal is to see if this combination can help patients live longer without their disease getting worse.
Alkylating agents
Oregovomab + Chemo for Advanced Ovarian Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
Recruiting3 awardsPhase 3
Birmingham, Alabama
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
Aromatase Inhibitor
Letrozole +/- Chemotherapy for Ovarian Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is testing whether Letrozole, with or without Paclitaxel and Carboplatin, can effectively treat patients with Stage II-IV Low-Grade Serous Carcinoma of the ovary, fallopian tube, or peritoneum.
Tyrosine Kinase Inhibitor
Olaparib vs. Cediranib + Olaparib for Recurrent Ovarian Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is comparing two different treatments for ovarian, fallopian tube, or primary peritoneal cancer that has come back. One treatment is a standard chemotherapy treatment, and the other is a new treatment that uses two drugs, olaparib and cediranib maleate. The trial will see if the new treatment is more effective than the standard chemotherapy treatment.
Trials With No Placebo
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
Recruiting1 awardPhase 1
Iowa City, Iowa
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
Corticosteroid
Relacorilant + Nab-Paclitaxel for Ovarian Cancer
Recruiting2 awardsPhase 3
Rapid City, South Dakota
This trial tests a new combination of two drugs for ovarian cancer patients who have no other treatment options left. The combination includes a drug that may make chemotherapy more effective and a chemotherapy drug that has been used in various cancer treatments. The goal is to see if this combination can help patients live longer without their disease getting worse.
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Checkpoint Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.